Since there are multiple drug targets in this pathway, including PIK3CA inhibitors, which are approved for breast cancer, and AKT1 inhibitors, the lower prevalence of mutations in this pathway may lead to worsening disparities in outcomes, as these treatments would not be efficacious in this group. This evidence concerns the gene PIK3CA and breast carcinoma.